<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11688">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00552812</url>
  </required_header>
  <id_info>
    <org_study_id>G060057</org_study_id>
    <nct_id>NCT00552812</nct_id>
  </id_info>
  <brief_title>Coarctation Of the Aorta Stent Trial</brief_title>
  <acronym>COAST</acronym>
  <official_title>Coarctation Of the Aorta Stent Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Richard E. Ringel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Cheatham Platinum bare metal stents are
      safe and effective in the treatment of native and recurrent aortic coarctation in selected
      children, adolescents and adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goals of this study are to provide information that will support labeling of both the CP
      bare metal and covered stents to treat native and recurrent aortic coarctation in selected
      children, adolescents and adults. The investigation will have two phases: Phase One will
      examine the safety and efficacy of the bare metal stent, and will collect information about
      the covered stent when used as rescue therapy for aortic injuries occurring during bare
      metal stent procedures.

      The aims of the Phase One study are to assess the use of the CP bare metal stent to:

        1. provide a reduction equivalent to surgery in arm-leg systolic cuff blood pressure
           gradient 12 months after dilation and stent implantation, in comparison to the
           pre-dilation gradient;

        2. accomplish gradient relief with a shorter number of days in hospital than surgery;

        3. accomplish gradient relief with a rate of occurrence of serious procedure-related
           adverse events occurring within 30 days of dilation that is equivalent to surgery; and

        4. accomplish gradient relief with a rate of occurrence of post-procedural paradoxical
           hypertension that is lower than surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Difference Between Arm and Leg Systolic Blood Pressure From Baseline to 12 Months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Noninvasive systolic blood pressures are measured in the arms and legs at baseline and 12 month follow-up. The difference between these measurements are calculated. The difference between systolic arm and leg blood pressures decreased by 30 Â± 22 mmHg (n=90)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Systolic Blood Pressure Greater Than the 95th Percentile for Age and Gender 12 Months Post Stent Placement</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Noninvasive Blood pressure is assessed at baseline and 12 months. The number of patients with a Systolic Blood Pressure &gt; 95th Percentile for Age and Gender is recorded at Baseline (n=105) and compared to 12 month follow up (n=92).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure, Difference Between Upper and Lower Extremities</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of difference between upper and lower extremities by noninvasive, automated measurement of four quadrant Systolic Blood Pressure. Comparison between baseline and 12 month follow up.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Coarctation of the Aorta</condition>
  <arm_group>
    <arm_group_label>Stent therapy of aortic coarctation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stenting of aortic coarctation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stent therapy of aortic coarctation</intervention_name>
    <description>Transcatheter delivery of a metallic stent to enlarge region of aortic narrowing caused by the coarctation.</description>
    <arm_group_label>Stent therapy of aortic coarctation</arm_group_label>
    <other_name>Cheatham-Platinum Stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Native or recurrent aortic coarctation

          -  Weight greater than or equal to 35 kg

          -  Noninvasive, arm-leg cuff systolic blood pressure difference or catheter measured
             systolic coarctation gradient greater than or equal to 20 mmHg

        Exclusion Criteria:

          -  Age &gt; 60 years

          -  Connective tissue disorders, including Marfan syndrome and other genetic syndromes
             such as Turner syndrome and Noonan syndrome

          -  Inflammatory aortitis

          -  Bloodstream infection, including endocarditis

          -  Pregnancy

          -  Aortic aneurysm

          -  Prior stent placement

          -  Adults lacking capacity to consent

          -  Foster children and/or wards of the court
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard E Ringel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathy Jenkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 14, 2016</lastchanged_date>
  <firstreceived_date>October 31, 2007</firstreceived_date>
  <firstreceived_results_date>September 19, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Richard E. Ringel</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Aortic Coarctation</keyword>
  <keyword>Heart Defects, Congenital</keyword>
  <keyword>Stents</keyword>
  <keyword>Heart Catheterization</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Coarctation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment opened February, 2008 and ended December, 2010</recruitment_details>
      <pre_assignment_details>Patients were consented as outpatients, but final selection criteria were assessed in the catheterization laboratory</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Coarctation Stenting</title>
          <description>Stent enlargement of aortic coarctation : Transcatheter delivery of a metallic stent to enlarge region of aortic narrowing caused by the coarctation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105">168 consents, 57 failed cath criteria, 5 met criteria but received covered stent, 1 withdrew consent</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85">Some still remain inside the 2 year follow up window. 2 year follow up data is not yet complete.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Coarctation Stenting</title>
          <description>Stent enlargement of aortic coarctation : Transcatheter delivery of a metallic stent to enlarge region of aortic narrowing caused by the coarctation.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="105"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="67"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="38"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="16" lower_limit="8" upper_limit="52"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="32"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="73"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="105"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Difference Between Arm and Leg Systolic Blood Pressure From Baseline to 12 Months</title>
        <description>Noninvasive systolic blood pressures are measured in the arms and legs at baseline and 12 month follow-up. The difference between these measurements are calculated. The difference between systolic arm and leg blood pressures decreased by 30 Â± 22 mmHg (n=90)</description>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Coarctation Stenting</title>
            <description>Stent enlargement of aortic coarctation: Transcatheter delivery of a metallic stent to enlarge region of aortic narrowing caused by the coarctation.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="90"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Difference Between Arm and Leg Systolic Blood Pressure From Baseline to 12 Months</title>
            <description>Noninvasive systolic blood pressures are measured in the arms and legs at baseline and 12 month follow-up. The difference between these measurements are calculated. The difference between systolic arm and leg blood pressures decreased by 30 Â± 22 mmHg (n=90)</description>
            <units>mmHg</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30" spread="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Systolic Blood Pressure Greater Than the 95th Percentile for Age and Gender 12 Months Post Stent Placement</title>
        <description>Noninvasive Blood pressure is assessed at baseline and 12 months. The number of patients with a Systolic Blood Pressure &gt; 95th Percentile for Age and Gender is recorded at Baseline (n=105) and compared to 12 month follow up (n=92).</description>
        <time_frame>Baseline and 12 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>Study patients compared at baseline and within the 12 month follow up window: Baseline (n=105) compared to 12 month follow up (n=92)</population>
        <group_list>
          <group group_id="O1">
            <title>Coarctation Stenting</title>
            <description>Stent enlargement of aortic coarctation: Transcatheter delivery of a metallic stent to enlarge region of aortic narrowing caused by the coarctation.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With a Systolic Blood Pressure Greater Than the 95th Percentile for Age and Gender 12 Months Post Stent Placement</title>
            <description>Noninvasive Blood pressure is assessed at baseline and 12 months. The number of patients with a Systolic Blood Pressure &gt; 95th Percentile for Age and Gender is recorded at Baseline (n=105) and compared to 12 month follow up (n=92).</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>12 month follow up</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure, Difference Between Upper and Lower Extremities</title>
        <description>Measurement of difference between upper and lower extremities by noninvasive, automated measurement of four quadrant Systolic Blood Pressure. Comparison between baseline and 12 month follow up.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>Comparison between baseline(n=105) and 12 month follow up (n=92)</population>
        <group_list>
          <group group_id="O1">
            <title>Coarctation Stenting</title>
            <description>Stent enlargement of aortic coarctation: Transcatheter delivery of a metallic stent to enlarge region of aortic narrowing caused by the coarctation.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Systolic Blood Pressure, Difference Between Upper and Lower Extremities</title>
            <description>Measurement of difference between upper and lower extremities by noninvasive, automated measurement of four quadrant Systolic Blood Pressure. Comparison between baseline and 12 month follow up.</description>
            <units>mmHg</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29" spread="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>12 months</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1" spread="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Coarctation Stenting</title>
          <description>Stent enlargement of aortic coarctation : Transcatheter delivery of a metallic stent to enlarge region of aortic narrowing caused by the coarctation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal exercise echo test at one year</sub_title>
                <description>Hypertension on exercise testing related to residual stent narrowing</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Post-procedure hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Residual aortic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Stent Malposition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>AV Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Localized vascular tear</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Groin Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Richard E. Ringel</name_or_title>
      <organization>Johns Hopkins School of Medicine</organization>
      <phone>410-614-6745</phone>
      <email>rringel@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
